|
Market Closed -
Nasdaq
01:30:00 19/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 22.14 USD | -2.60% |
|
-2.85% | - |
| 16/09 | Attovia Therapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 10:00 AM | |
| 03/09 | Attovia Therapeutics Q2 Net Loss Widens | MT |
Projected Income Statement: Attovia Therapeutics, Inc.
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Net sales 1 | - | 0.4667 | - | - |
| Change | - | - | - | - |
| EBITDA 1 | - | -89.96 | -119.9 | -140.3 |
| Change | - | - | -33.27% | -17.01% |
| EBIT 1 | - | -90.61 | -120 | -141.3 |
| Change | - | - | -32.47% | -17.75% |
| Interest Paid | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - |
| Change | - | - | - | - |
| Net income 1 | -60.9 | -83.44 | -107.1 | -135.7 |
| Change | - | -37.02% | -28.41% | -26.62% |
| Announcement Date | 14/07/26 | - | - | - |
1USD in Million
Estimates
Forecast Balance Sheet: Attovia Therapeutics, Inc.
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Net Debt 1 | - | -379 | -286 | -508 |
| Change | - | - | 24.54% | -77.62% |
| Announcement Date | 14/07/26 | - | - | - |
1USD in Million
Estimates
Cash Flow Forecast: Attovia Therapeutics, Inc.
| Fiscal Period: December | 2026 | 2027 | 2028 |
|---|---|---|---|
| CAPEX 1 | 3.238 | 4.21 | 5.052 |
| Change | - | 30.02% | 20% |
| Free Cash Flow (FCF) 1 | -93.94 | -114 | -132.3 |
| Change | - | -21.32% | -16.04% |
| Announcement Date | - | - | - |
1USD in Million
Estimates
Forecast Financial Ratios: Attovia Therapeutics, Inc.
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
Profitability | ||||
| EBITDA Margin (%) | - | -19,276.24% | - | - |
| EBIT Margin (%) | - | -19,415.51% | - | - |
| EBT Margin (%) | - | - | - | - |
| Net margin (%) | - | -17,880.2% | - | - |
| FCF margin (%) | - | -20,130.93% | - | - |
| FCF / Net Income (%) | - | 112.59% | 106.37% | 97.48% |
Profitability | ||||
| ROA | - | - | - | - |
| ROE | - | -472.93% | -97.66% | -31.8% |
Financial Health | ||||
| Leverage (Debt/EBITDA) | - | - | - | - |
| Debt / Free cash flow | - | - | - | - |
Capital Intensity | ||||
| CAPEX / Current Assets (%) | - | 693.85% | - | - |
| CAPEX / EBITDA (%) | - | -3.6% | -3.51% | -3.6% |
| CAPEX / FCF (%) | - | -3.45% | -3.69% | -3.82% |
Items per share | ||||
| Cash flow per share 1 | - | - | - | - |
| Change | - | - | - | - |
| Dividend per Share 1 | - | - | - | - |
| Change | - | - | - | - |
| Book Value Per Share 1 | - | 8.23 | 5.94 | 9.24 |
| Change | - | - | -27.83% | 55.56% |
| EPS 1 | -1.66 | -2.779 | -2.096 | -2.437 |
| Change | - | -67.39% | 24.59% | -16.29% |
| Nbr of stocks (in thousands) | - | 45,651 | 45,651 | 45,651 |
| Announcement Date | 14/07/26 | - | - | - |
1USD
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E | -8.18x | -10.8x |
| PBR | 2.76x | 3.83x |
| EV / Sales | 1,411x | - |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Year-on-year evolution of the Yield
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
22.73USD
Average target price
42.20USD
Spread / Average Target
+85.66%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ATTO Stock
- Financials Attovia Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
